[go: up one dir, main page]

BRPI0809595A2 - "Polypeptide, nucleic acid sequence, vector, host, process for production of a polypeptide, pharmaceutical composition, use of a polypeptide, method for the prevention, treatment or improvement of a disease" - Google Patents

"Polypeptide, nucleic acid sequence, vector, host, process for production of a polypeptide, pharmaceutical composition, use of a polypeptide, method for the prevention, treatment or improvement of a disease"

Info

Publication number
BRPI0809595A2
BRPI0809595A2 BRPI0809595-7A2A BRPI0809595A BRPI0809595A2 BR PI0809595 A2 BRPI0809595 A2 BR PI0809595A2 BR PI0809595 A BRPI0809595 A BR PI0809595A BR PI0809595 A2 BRPI0809595 A2 BR PI0809595A2
Authority
BR
Brazil
Prior art keywords
polypeptide
vector
host
disease
prevention
Prior art date
Application number
BRPI0809595-7A2A
Other languages
Portuguese (pt)
Inventor
Peter Kufer
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Priority claimed from PCT/EP2008/002663 external-priority patent/WO2008119566A2/en
Publication of BRPI0809595A2 publication Critical patent/BRPI0809595A2/en

Links

BRPI0809595-7A2A 2007-04-03 2008-04-03 "Polypeptide, nucleic acid sequence, vector, host, process for production of a polypeptide, pharmaceutical composition, use of a polypeptide, method for the prevention, treatment or improvement of a disease" BRPI0809595A2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP07006990 2007-04-03
EP07006988 2007-04-03
US91366807P 2007-04-24 2007-04-24
EP07020641 2007-10-22
EP07020646 2007-10-22
EP07020640 2007-10-22
PCT/EP2008/002663 WO2008119566A2 (en) 2007-04-03 2008-04-03 Cross-species-specific bispecific binders

Publications (1)

Publication Number Publication Date
BRPI0809595A2 true BRPI0809595A2 (en) 2015-02-10

Family

ID=52472669

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809595-7A2A BRPI0809595A2 (en) 2007-04-03 2008-04-03 "Polypeptide, nucleic acid sequence, vector, host, process for production of a polypeptide, pharmaceutical composition, use of a polypeptide, method for the prevention, treatment or improvement of a disease"

Country Status (1)

Country Link
BR (1) BRPI0809595A2 (en)

Similar Documents

Publication Publication Date Title
BRPI0906786A2 (en) Compound, process for preparing a compound, use of a compound, method for treating a disease or condition, pharmaceutical composition, process for preparing a pharmaceutical composition, product, and kit.
BRPI1009022A2 (en) "compound, pharmaceutical composition, process for producing a pharmaceutical composition, use of a compound, method for treating a disease or disorder and kit"
BRPI0821299A2 (en) Compound, process for preparing same, pharmaceutical composition, process for preparing same, use of a compound, and method for treating or reducing the risk of a disease or condition.
BRPI0915084A2 (en) compound, process for preparing a compound, pharmaceutical composition, use of a compound, methods for the prophylaxis or treatment of a disease state or condition and cancer
BRPI0720637A2 (en) COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, STEREOISOMIC, TAUTOMERIC OR POLYMORPHIC FORM OF THEREOF, METHODS FOR TREATING A HOST AND INFECTION, PHARMACEUTICAL COMPOSITION, AND, USE OF THE COMPOUND
BRPI0807269A2 (en) "ISOLATED ANTAGONIST ANTIBODY, ISOLATED NUCLEIC ACID MOLLECLE, VECTOR, HOST CELL, COMPOSITION, TREATMENT METHOD, METHOD FOR REDUCING ASVERT SEVERITY, ASMATEDO MODOTE TO PRODUCT, MODRESS OF THE ANTOD FOR PRODUCT, , KITS AND MEDICAL APPLIANCES "
BRPI0816330A2 (en) Polypeptide composition, method for producing polypeptide composition, polypeptide construct, method for producing a polypeptide construct, nucleic acid construct, medicament or vaccine composition, method for producing a medicament or vaccine composition, and use of the polypeptide composition , a polypeptide construct, a nucleic acid construct or a medicament or vaccine composition
BRPI0717822A2 (en) COMPOUND, COMPOUND MANUFACTURING PROCESS OF FORMULA I, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND / OR PROPHYLAXY OF DISEASES WHICH ARE ASSOCIATED WITH THE MODULATION OF CB2 RECEPTORS AND USE OF COMPOUND.
BRPI0906064A2 (en) "peptide, process for obtaining a peptide of formula (i), cosmetic or pharmaceutical composition and use of a peptide of formula (i)"
BRPI0819799A2 (en) Compound, intermediate, use of a compound, pharmaceutical composition, and method for preventing, treating or ameliorating a disease
BRPI0811267A2 (en) PHENYLANINE VARIANT, PROCARIOTIC AMMONIA-LIASIS, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATMENT OF A DISEASE, USE OF A PHENYLANANINE VARIANT, PROCARIOTIC AMENIA-LIASE, VARIANAL DEHYLENE CONDITION METHOD
CL2007003502A1 (en) COMPOUNDS DERIVED FROM PYRIMIDIN-AMINA, JNK MODULATORS; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITIONS; AND USE FOR THE TREATMENT OF REUMATOID ARTHRITIS, ASTHMA, TYPE II DIABETES, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE AND APOPLEJIA.
BRPI1009576A2 (en) antibody, neutralizing antibody molecule, isolated DNA sequence, cloning or expression vector, host cell, process for producing the antibody, pharmaceutical composition, use of an antibody, and method for treating a patient.
BRPI0906104A2 (en) "peptide nucleic acid derivative, pharmaceutical composition containing a therapeutically effective amount of the peptide nucleic acid derivative, pharmaceutical composition containing a therapeutically effective amount of the peptide nucleic acid derivative, method of using the peptide nucleic acid derivative and compound"
BR112013013435A2 (en) compound, pharmaceutical composition, use of a compound, method for the prophylaxis or treatment of a gfr kinase mediated disease condition or condition, and process for the preparation of a compound.
BRPI1013396A2 (en) compound, combination pharmaceutical, use of a compound, method for treating a disease or condition, and process for the preparation of a compound.
BRPI0909768A2 (en) compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by activation of b3-adrenoceptor, and use of a compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by b3-adrenoceptor. b3-adrenoceptor activation, and use of a compound
BRPI0713000A8 (en) SINGLE CHAIN MULTIESPECIFIC BINDING PROTEIN, PHARMACEUTICAL COMPOSITION AND USE OF SAID SINGLE CHAIN MULTIESPECIFIC BINDING PROTEIN
BRPI0814781A2 (en) PROTEIN, NUCLEIC ACID SEQUENCE, METHOD FOR THE PRODUCTION OF ITAONIC ACID, VECTOR, HOST CELL, AND USE OF A CIS-ACONYTIC ACID
BRPI0820576A2 (en) "Smallpox virus, process for preparing it, composition, use of a smallpox virus or composition, and method for treating disease"
EP1937683A4 (en) PROCESS FOR THE PREPARATION OF 1H-IMIDAZOÝ4,5-CYPYRIDINES AND ANALOGS THEREOF
BRPI0819755A2 (en) compound, pharmaceutical composition, processes for preparing a compound and a pharmaceutical composition, use of a compound, and method for treating or reducing the risk of an inflammatory disease or condition
BRPI0716680A2 (en) "compound, multimer, composition, method of affecting the activity of a target, complex, process of production of compound, method of production of a consecutive amino acid extension, process of production of a consecutive amino acid extension, process for production of a compound, method of producing a protein and polypeptide "
BRPI0715531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATMENT OF A NURSING AND / OR METABOLIC DISORDER, PROCESS FOR PREPARATION OF COMPOUNDS AND USE OF COMPOUND
BRPI0717768A2 (en) ANTIBODY, EPITIP, ISOLATED DNA SEQUENCE, CLONING OR EXPRESSION VECTOR, HOST CELL, PROCESS FOR ANTIBODY PRODUCTION, PHARMACEUTICAL COMPOSITION, AND, USE OF AN ANTIBODY

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: MICROMET AG (DE)

Free format text: A FIM DE ATENDER AS DUAS ALTERACOES DE NOME REQUERIDAS ATRAVES DA PETICAO NO 20120113074/RJ, DE 06/12/2012, E NECESSARIO APRESENTAR MAIS UMA GUIA RELATIVA A SEGUNDA ALTERACAO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: MICROMET GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: AMGEN RESEARCH (MUNICH) GMBH (DE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.